Genome-Wide Association Study With the Aim of Implantable Cardioverter Defibrillator Implantation Genophenotypic Risk Stratification
Launched by SELCUK UNIVERSITY · Oct 12, 2022
Trial Information
Current as of July 25, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ICD-implanted patients (both for primary and secondary intervention)
- • Being a volunteer for the study
- • Adequacy in understanding the study risks and accepting the Informed Consent Form
- • Official acceptance of the legal and official parents (both father and mother), If younger than 18 years old
- Exclusion Criteria:
- • The patient who does not volunteer to involve to the study.
- • Diagnosis of underlying arrhythmogenic disease (Structural Heart disease, Brugada, Arrhythmogenic right ventricular dysplasia, etc.)
- • Development of electric shock due to acute coronary syndrome
- • Atrial Fibrillation (AFib) With Rapid Ventricular Response
- • Electric shock in patients with electrolyte imbalance-induced VT/VF
- • Electric Shock in a patient with acute myocarditis-induced ventricular arrhythmias
- • Patients that had an electric shock because of pacing / ATP ramp-induced VT (RV/CRT Pacing)
About Selcuk University
Selçuk University is a prominent educational institution located in Turkey, recognized for its commitment to advancing medical research and clinical studies. As a clinical trial sponsor, Selçuk University leverages its extensive academic resources and expertise to conduct innovative research that aims to address significant healthcare challenges. The university fosters collaboration among researchers, healthcare professionals, and industry partners to facilitate the development of new therapies and improve patient outcomes. Through rigorous adherence to ethical standards and regulatory guidelines, Selçuk University strives to contribute to scientific knowledge and enhance the quality of care within the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Konya, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials